Primaquine for preventing relapses in people with Plasmodium vivax malaria

Cochrane Database of Systematic Reviews

Volumn , Issue 1, 2007, Pages

  Galappaththy, Gawrie N L ^a   Omari, A A A ^b   Tharyan, P ^b  

^a MINISTRY OF HEALTH   (Sri Lanka)

^b NONE

Author keywords

Adult; Antimalarials *therapeutic use ; Child; Chloroquine therapeutic use ; Humans; Malaria, vivax *prevention control ; Primaquine *therapeutic use ; Randomized controlled trials as topic; Recurrence prevention control

Indexed keywords

CHLOROQUINE; PRIMAQUINE;

ABDOMINAL PAIN; CYANOSIS; DRUG ABSORPTION; DRUG HALF LIFE; DRUG MECHANISM; HEADACHE; HEART ARRHYTHMIA; HEMOLYSIS; HUMAN; HYPERTENSION; LEUKOPENIA; MALARIA; METHEMOGLOBINEMIA; NAUSEA; PARASITEMIA; PLASMODIUM VIVAX; RASH; RELAPSE; REVIEW; SINGLE DRUG DOSE; VERTIGO; VOMITING;

EID: 38649142530     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD004389.pub2     Document Type: Review

References (64)

1. Gogtay 1999 {published data only} Gogtay NJ, Deshai S, Kamtekar KD, Kadam VS, Dalvi SS, Kshirsagar NA. Efficacies of 5 and 14 day primaquine regimens in the prevention of relapses in Plasmodium vivax infections. Annals of Tropical Medicine and Parasitology 1999;93(8):809-12.
2. Leslie 2004 {published data only} Leslie T, Rab MA, Ahmadzai H, Durrani N, Fayaz M, Kolaczinski J, et al.Compliance with 14-day primaquine therapy for radical cure of vivax malaria - a randomized placebo-controlled trial comparing unsupervised with supervised treatment. Transactions of the Royal Society of Tropical Medicine and Hygiene 2004;98(3):168-73.
3. Pukrittayakamee 1994 {published data only} Pukrittayakamee S, Vanijanonta S, Chantra A, Clemens R, White NJ. Blood stage antimalarial efficacy of primaquine in Plasmodium vivax malaria. Journal of Infectious Diseases 1994;169(4):932-5.
4. Rajgor 2003 {published data only} Rajgor DD, Gogtay NJ, Kadam VS, Kamtekar KD, Dalvi SS, Chogle AR, et al.Efficacy of a 14-day primaquine regimen in preventing relapses in patients with Plasmodium vivax malaria in Mumbai, India. Transactions of the Royal Society of Tropical Medicine and Hygiene 2003; 1997:438-40.
5. Rowland 1999i {published data only} Rowland M, Durrani N. Randomized controlled trials of 5- and 14-days primaquine therapy against relapses of vivax malaria in an Afghan refugee settlement in Pakistan. Transaction of the Royal Society of Tropical Medicine and Hygiene 1999;93(6):641-3.
6. Rowland1999ii {published data only} Rowland M, Durrani N. Randomized controlled trials of 5- and 14-days primaquine therapy against relapses of vivax malaria in an Afghan refugee settlement in Pakistan. Transactions of the Royal Society of Tropical Medicine and Hygiene 1999;93(6):641-3.
7. Villalobos 2000 {published data only} Villalobos-Salcedo JM, Tada MS, Kimura E, Menezes MJ, Pereira da Silva LH. In-vivo sensitivity of Plasmodium vivax isolates from Rond nia (western Amazon region, Brazil) to regimens including chloroquine and primaquine. Annals of Tropical Medicine and Parasitology 2000;94(8):749-58.
8. Walsh 2004 {published data only} Walsh DS, Wilairatana P, Tang DB, Heppner DG Jr, Brewer TG, Krudsood S, et al.Randomized trial of 3-dose regimens of tafenoquine (WR238605) versus low-dose primaquine for preventing Plasmodium vivax malaria relapse. Clinical Infectious Diseases 2004;39 (8):1095-103.
9. Yadav 2002 {published data only} Yadav RS, Ghosh SK. Radical curative efficacy of 5 day regimen of primaquine for treatment pf Plasmodium vivax malaria in India. Journal of Parasitology 2002;88(5):1042-4.
10. Abdon 2001 Abdon NP, Pinto AY, das Silva Rdo S, de Souza JM. Assessment of the response to reduced treatment schemes for vivax malaria. Revista da Sociedade Brasileira de Medicina Tropical 2001;34(4): 343-8.
11. Appavoo 1984 Appavoo NC, Roy RG, Kapali V. Results of 3-day radical treatment of Plasmodium vivax in North Arcot and South Arcot Districts of Tamil Nadu. Indian Journal of Malariology 1984;21(1):21-4.
12. Baird 1995 Baird JK, Fryauff DJ, Basri H, Bangs MJ, Subianto B, Wiady I, et al.Primaquine for prophylaxis against malaria among nonimmune transmigrants in Irian Jaya, Indonesia. American Journal of Tropical Medicine and Hygiene 1995;52(6):479-84.
13. Baird 2001 Baird JK, Lacy MD, Basri H, Barcus MJ, Maguire JD, Bangs MJ, et al.Randomized, parallel placebo-controlled trial of primaquine for malaria prophylaxis in Papua, Indonesia. Clinical Infectious Diseases 2001;33(12):1990-7.
14. Baird 2003 Baird JK, Fryauff DJ, Hoffman SL. Primaquine for prevention of malaria in travelers. Clinical Infectious Diseases 2003;37(12):1659-67.
15. Basavaraj 1960 Basavaraj HR. Observations on the treatment of 678 malaria cases with primaquine in an area free from malaria transmission in Mysore State, India. Indian Journal of Malariology 1960;14:269-81.
16. Buchachart 2001 Buchachart K, Krudsood S, Singhasivanon P, Treeprasertsuk S, Phophak N, Srivilairit S, et al.Effect of primaquine standard dose (15 mg/day for 14 days) in the treatment of vivax malaria patients in Thailand. Southeast Asian Journal of Tropical Medicine and Public Health 2001;32(4):720-6.
17. Bunnag 1994 Bunnag D, Karbwang J, Thanavibul A, Chittamas S, Ratanapongse Y, Chalermrut K, et al.High dose of primaquine in primaquine resistant vivax malaria. Transactions of the Royal Society of Tropical Medicine and Hygeine 1994;88(2):218-9.
18. Cedillos 1978 Cedillos RA, Warren M, Jeffery GM. Field evaluation of primaquine in the control of Plasmodium vivax. American Journal of Tropical Medicine and Hygiene 1978;27(3):466-72.
19. Clyde 1977 Clyde DF, McCarthy VC. Radical cure of Chesson strain vivax malaria in man by 7, not 14, days of treatment with primaquine. American Journal of Tropical Medicine and Hygiene 1977;26(3):562- 3.
20. Contacos 1974 Contacos PG, Collins WE, Chin W, Jeter MH, Briesch PE. Combined chloroquine-primaquine therapy against vivax malaria. American Journal of Tropical Medicine and Hygiene 1974;23(2):310-2.
21. da Silva 2003 da Silva Rdo S, Pinto AY, Calvosa VS, de Souza JM. Short course schemes for vivax malaria treatment [Esquemas terapeuticos encurtados para o tratamento de malaria por Plasmodium vivax]. Revista da Sociedade Brasileira de Medicina Tropica 2003;36(2):235-9.
22. Dua 2001 Dua VK, Sharma VP. Plasmodium vivax relapses after 5 days of primaquine treatment, in some industrial complexes of India. Annals of Tropical Medicine and Parasitology 2001;95(7):655-9.
23. Fryauff 1997 Fryauff DJ, Baird JK, Purnomo, Awalludin M, Jones T, Subianto B, et al.Malaria in a nonimmune population after extended chloroquine or primaquine prophylaxis. American Journal of Tropical Medicine and Hygiene 1997;56(2):137-40.
24. Gogtay 1998 Gogtay N, Garg M, Kadam V, Kamtekar K, Kshirsagar NA. A 5 days primaquine regimen as anti-relapse therapy for Plasmodium vivax. Transactions of the Royal Society of Tropical Medicine and Hygiene 1998; 92(3):341.
25. Looareesuwan 1999 Looareesuwan S, Wilairatana P, Krudsood S, Treeprasertsuk S, Singhasivanon P, Bussaratid V, et al.Chloroquine sensitivity of Plasmodium vivax in Thailand. Annals of Tropical Medicine and Parasitology 1999;93(3):225-30.
26. Luxemburger 1999 Luxemburger C, van Vugt M, Jonathan S, McGready R, Looareesuwan S, White NJ, et al.Treatment of vivax malaria on the western border of Thailand. Transactions of the Royal Society of Tropical Medicine and Hygiene 1999;93(4):433-8.
27. Pinto 1998 Pinto AY, Ventura AM, Calvosa VS, Silva Filho MG, Santos MA, Silva RS, et al.Clinical efficacy of four schemes for vivax malaria treatment in children. Jornal de Pediatria 1998;74(3):222-7.
28. Prasad 1991 Prasad RN, Virk KJ, Sharma VP. Relapse/reinfection patterns of Plasmodium vivax infection: a four year study. Southeast Asian Journal of Tropical Medicine and Public Health 1991;22(4):499-503.
29. Roy 1977 Roy RG, Chakrapani KP, Dhinagaran D, Sitaraman NL, Ghosh RB. Efficacy of 5-day radical treatment of P. vivax infection in Tamil Nadu. Indian Journal of Medical Research 1977;65(5):652-6.
30. Saint-Yves 1977 Saint-Yves IF. Comparison of treatment schedules for Plasmodium vivax infections in the Solomon Islands. Papua New Guinea Medical Journal 1977;20(2):62-5.
31. Schwartz 2000 Schwartz E, Regev-Yochay G, Kurnik D. Short report: a consideration of primaquine dose adjustment for radical cure of Plasmodium vivax malaria. American Journal of Tropical Medicine and Hygiene 2000;62 (3):393-5.
32. Sharma 1973 Sharma MID, Sehgal PN, Vaid BK, Dubey RC, Nagendra S, Paithne PK, et al.Effectiveness of drug schedule being followed under the National Malaria Eradication Programme, India, for radical cure of vivax malaria cases. Journal of Communicable Diseases 1973;5:167-74.
33. Singh 1990 Singh N, Mishra AK, Sharma VP. Radical treatment of vivax malaria in Madhya Pradesh, India. Indian Journal of Malariology 1990;27(1): 55-6.
34. Sinha 1989 Sinha S, Dua VK, Sharma VP. Efficacy of 5 day radical treatment of primaquine in Plasmodium vivax cases at the BHEL industrial complex, Hardwar (U.P.). Indian Journal of Malariology 1989;26(2): 83-6.
35. Soto 1998 Soto J, Toledo J, Rodriquez M, Sanchez J, Herrera R, Padilla J, et al.Primaquine prophylaxis against malaria in nonimmune Colombian soldiers: efficacy and toxicity. A randomized, double-blind, placebo-controlled trial. Annals of Internal Medicine 1998;129(3): 241-4.
36. Soto 1999 Soto J, Toledo J, Rodriquez M, Sanchez J, Herrera R, Padilla J, et al.Double-blind, randomized, placebo-controlled assessment of chloroquine/primaquine prophylaxis for malaria in nonimmune Colombian soldiers. Clinical Infectious Diseases 1999;29(1):199-201.
37. Valibayov 2003 Valibayov A, Abdullayev F, Mammadov S, Gasimov E, Sabatinelli G, Kondrachine AV, et al.Clinical efficacy of chloroquine followed by primaquine for Plasmodium vivax treatment in Azerbaijan. Acta Tropica 2003;88(1):99-102.
38. Rowland 2004 Rowland M, Leslie T, Durrani NM (Gates Malaria Partenship & HealthNet International). Eight week Primaquine regimen for the treatment of vivax malaria [ClinicalTrials.gov Identifier:NCT00158587]. www.clinicaltrials.gov/ct/show/NCT00158587 2005.
39. Adak 2001 Adak T, Valecha N, Sharma VP. Plasmodium vivax polymorphism in a clinical drug trial. Clinical and Diagnostic Laboratory Immunology 2001;8(5):891-4.
40. Baird 2004 Baird JK, Hoffman SL. Primaquine therapy for malaria. Clinical Infectious Diseases 2004;39(9):1336-45.
41. Beutler 1994 Beutler E. G6PD deficiency. Blood 1994;84(11):3613-36.
42. Breman 2001 Breman 2001. The ears of the hippopotamus: manifestations, determinants, and estimates of the malaria burden. American Journal of Medicine and Hygiene 2001;64 Suppl 1-2:1-11.
43. CDC 2005 Centers for Disease Control and Prevention, Kozarsky PE, Arguin PM, Navin AW. Health Information for International Travel 2005-2006. Philadelphia: Elsevier, 2005.
44. Charoenlarp 1973 Charoenlarp P, Harinasuta T. Relapses of vivax malaria after a conventional course of primaquine and chloroquine: report of 2 cases. Southeast Asian Journal of Tropical Medicine and Public Health 1973; 4(1):135-6.
45. Cogswell 1992 Cogswell FB. The hypnozoites and relapse in primate malaria. Clinical Microbiology Review 1992;5(1):26-35.
46. Collins 1996 Collins WE, Jeffery GM. Primaquine resistance in P. vivax. American Journal of Tropical Medicine and Hygiene 1996;55(3):243-9.
47. Craig 1996 Craig AA, Kain KC. Molecular analysis of strains of Plasmodium vivax from paired primary and relapse infections. Journal of Infectious Diseases 1996;174(2):373-9.
48. Deeks 2005 Deeks JJ, Higgins, JPT, Altman DG, editors. Analysing and presenting results. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 updated May 2005; Appendix 5b. In: HigginsJPT, GreenS editor(s). www.cochrane.org/resources/handbook/hbook.htm. (accessed 1 June 2006).
49. Divine 1992 Divine GW, Brown JT, Frazier LM. The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine 1992;7(6):623-9.
50. Fonseka 1987 Fonseka J, Mendis KN. A metropolitan hospital in a non-endemic area provides a sampling pool for epidemiological studies on vivax malaria in Sri Lanka. Transactions of the Royal Society of Tropical Medicine and Hygiene 1987;81(3):360-4.
51. Haynes 2005 Haynes RB, Yao X, Degani A, Kripalani S, Garg A, McDonald HP. Interventions to enhance medication adherence. Cochrane Database of Systematic Reviews 2005, Issue 4.
52. Higgins 2003 Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557- 60.
53. Higgins 2005 Higgins JPT, Green S, editors. Highly sensitive search strategies for identifying reports of randomized controlled trials in MEDLINE. Cochrane Handbook for Systematic Reviews of Interventions [4.2.5] updated [May 2005]; Appendix 5b. www.cochrane.org/resources/handbook/hbook.htm (accessed 1 January 2006).
54. Hill 2006 Hill DR, Baird JK, Parise ME, Lewis LS, Ryan ET, Magill AJ. Primaquine: Report from CDC expert meeting on malaria chemoprophylaxis I. American Journal of Tropical Medicine and Hygeine 2006; 75(3):402-15.
55. Juni 2001 Juni P, Altman DG, Egger M. Systematic reviews in health care: Assessing the quality of controlled clinical trials. BMJ 2001;323(7303):42-6.
56. Krudsood 2006 Krudsood S, Wilairatana P, Tangpukdee N, Chalermrut K, Srivilairit S, Thanachartwet V, et al.Safety and tolerability of elubaquine (bulaquine, CDRI 80/53) for treatment of Plasmidium vivax malaria in Thailand. Korean Journal of Parasitology 2006;44(3):221-8.
57. Looareesuwan 1997 Looareesuwan S, Buchachart K, Wilairatana P, Chalermrut K, Rattanapong Y, Amradee S, et al.Primaquine-tolerant vivax malaria in Thailand. Annals of Tropical Medicine and Hygiene 1997;91(8): 939-43.
58. Mendis 2001 Mendis K, Sina JB, Marchesini P, Carter R. The neglected burden of P. vivax malaria. American Journal of Medicine and Hygiene 2001;64 Suppl 1-2:97-106.
59. Moher 2001 Moher D, Schulz KF, Altman D, CONSORT Group (Consolidated Standards of Reporting Trials). The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA 2001;285(15):1987-91.
60. Orton 2005 Orton L, Barnish G. Unit-dose packaged drugs for treating malaria. Cochrane Database of Systematic Reviews 2005, Issue 2.Art. No.: CD004614. DOI:10.1002/14651858.CD004614.pub2.
61. Parfitt 1999 Parfitt K, editor. Martindale: the complete drug reference. 2nd Edition. London: Pharmaceutical Press, 1999.
62. Qingjun 1998 Qingjun L, Jihui D, Laiyi T, Xiangjun Z, Jun L, Hay A, et al.The effect of drug packaging on patients' compliance with treatment for Plasmodium vivax malaria in China. Bulletin of the World Health Organization 1998;76 Suppl 1:21-7.
63. Review Manager 4.2 The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 4.2 for Windows. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2003.
64. WHO 2001 World Health Organzation, Global Partnership to Roll Back Malaria. The use of antimalarial drugs : report of a WHO informal consultation, 13-17 November 2000 [WHO/CDS/RBM/2001.33]. Geneva: World Health Organization, 2001.